Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9578 posts found.

bmslogo

BMS says Phase III trials for Opdivo show improved overall survival in lung cancer

May 19, 2016 Research and Development Bristol-Myers Squibb, drug trial, lung cancer, opdivo

Bristol-Myers Squibb (NYSE:BMY) said late-stage trials for its immuno-therapy Opdivo (nivolumab) showed improved overall survival in lung cancer at the …
News
rocheshanghai

FDA grants accelerated approval for Roche’s bladder cancer immunotherapy Tecentriq

May 19, 2016 Research and Development, Sales and Marketing FDA, Roche, atezolizumab, bladder cancer, immunotherapy, tecentriq

Roche (SIX: RO) has announced that the US Food and Drug Administration (FDA) has granted accelerated approval for Tecentriq (atezolizumab) …
News

AstraZeneca’s Lynparza fails to meet primary endpoint in Phase III gastric cancer trials

May 18, 2016 Research and Development AstraZeneca, failed to meet endpoint, gastric trail, lynparza, phase III

AstraZeneca has announced that its treatment for advanced gastric cancer, Lynparza (olaparib), failed to meet the primary endpoint of overall …
News
sample

Breast cancer trial stopped after meeting primary endpoint early

May 18, 2016 Research and Development LEE011, Novartis, breast cancer, progression free survival, ribociclib

A Phase III trial evaluating LEE011 (ribociclib), developed by Novartis, has been stopped early after a recommendation from an independent …
News
bi_german_building_at_night

Boehringer Ingelheim says new studies underline efficacy of lung disease drug

May 18, 2016 Research and Development, Sales and Marketing Boehringer Ingelheim, lung disease

Boehringer Ingelheim said late-stage trials for its drug to treat chronic lung disease reinstate its efficacy and safety profile. The …
News

Novartis splits pharmaceuticals division into two business units

May 18, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Novartis, epstein, new division

Novartis has announced internal structural changes that it says will “focus” its pharmaceuticals division by creating two business units, Novartis …
News
opdivo_1

Opdivo nabs FDA approval in specific patients with Hodgkin lymphoma

May 18, 2016 Research and Development, Sales and Marketing Bristol-Myers Squibb, Hodgkin lymphoma, opdivo

Bristol-Myers Squibb (NYSE: BMY) has announced that the US Food and Drug Administration (FDA) has approved Opdivo (nivolumab) for the …
News
michael_becker

Relmada Therapeutics appoints new chief financial officer

May 17, 2016 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing chief financial officer, relmada

Michael D. Becker has been appointed the new chief financial officer at Relmada Therapeutics. Becker joined the company in 2014 …
Appointment
biogen_idec_hillerod_2008

Biogen signs $2 billion partnership deal with UPenn for gene therapies

May 17, 2016 Research and Development, Sales and Marketing Biogen, collaboration, deal, gene therapy, research

Biogen (Nasdaq: BIIB) said it has signed a deal worth up to $2 billion with the University of Pennsylvania to …
News
astrazeneca_plaque

AstraZeneca says its respiratory biologic meets primary endpoint in Phase III trial

May 17, 2016 Manufacturing and Production, Research and Development AstraZeneca, asthma drug, benralizumab, drug trial

UK-based AstraZeneca (LSE: AZN) on Tuesday said late stage trials for its biologic asthma drug met the primary endpoint. Chief …
News
stocks3

Aduro’s pancreatic cancer immunotherapy fails Phase II trials; shares plunge

May 17, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Aduro Biotech, Pancreatic cancer, Stock, drug trial, markets

Shares in Aduro Biotech (Nasdaq: ADRO) dropped to closed down over 16% after the company said mid-stage trials of its …
News
mylan_building

Mylan to buy Renaissance’s dermatology business for up to $1 billion

May 16, 2016 Research and Development, Sales and Marketing Mylan, generics, merger and acquisition

Generics maker Mylan (Nasdaq: MYL) has agreed to buy skincare products from Renaissance Acquisition Holdings for up to $1 billion. …
News
sanofi_hq__boetie_hall

Sanofi to replace entire Medivation board to drive sale, according to reports

May 16, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Medivation, Sanofi, replace board, takeover

Reports have emerged that Sanofi is looking to step up its efforts to take over oncology firm, Medivation, as it …
News
stocks1

Weekly Movers: Teva, Midatech, Allergan…

May 16, 2016 Research and Development, Sales and Marketing Allergan, Ariad Pharmaceuticals, Lundbeck, Midatech Pharma, Stock, Teva Pharmaceutical, markets

We have hit the tail end of the earnings season and the near last batch of movers follow result pronouncements …
Feature
174571_1

Novartis says trials show its COPD drug more effective versus GSK’s Seretide

May 16, 2016 Research and Development, Sales and Marketing GSK, Novartis, drug trial, research

Swiss drug firm Novartis (VTX: NOVN) said its asthma drug showed efficacy over GlaxoSmithKline’s (LSE: GSK) medicine in a comparison …
News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026